Author Correction: Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions

1Scientific RepoRtS | (2020) 10:5665 | https://doi.org/10.1038/s41598-020-62492-z www.nature.com/scientificreports Author correction: Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions Marie-Laëtitia thézénas, Bianca De Leo, Alexis Laux-Biehlmann, cemsel Bafligil , Bernd elger, thomas t apmeier , Karl Morten, nilufer Rahmioglu, Stephanie G. Dakin, philip ch arles , fernando estrada Martinez, Graham Steers, oliver M. fi scher, Joerg Mueller, Holger Hess-Stumpp, Andreas Steinmeyer, Sanjiv Manek, Krina t. Zondervan , Stephen Kennedy, christian M. Becker , catherine Shang, thomas M. Zollner, Benedikt M. Kessler & Udo oppermann Correction to: Scientific Reports https://doi.org/10.1038/s41598-020-58362-3, published online 30 January 2020 In Figure 5A, the chemical structure is incorrect. As a result, the Figure legend, “ AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model. (A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H2O2 in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F ) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment. ” should read: “ AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model. (A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthe- sized according to literature procedures 37 (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H2O2 in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment. ” The correct Figure 5 and its accompanying legend appear below as Figure 1. Published: xx xx xxxx open 2Scientific RepoRtS | (2020) 10:5665 | https://doi.org/10.1038/s41598-020-62492-z www.nature.com/scientificreportswww.nature.com/scientificreports/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre- ative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not per- mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2020 Figure 1. AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model. (A) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures37 (B) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (C) Target engagement results (2 mg/kg). (D) Changes in H2O2 in plasma. (E) Plasma exposure of PXS-4681A at day 2. (F) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.